Cidofovir
- Generic Name
- Cidofovir
- Brand Names
- Vistide
- Drug Type
- Small Molecule
- Chemical Formula
- C8H14N3O6P
- CAS Number
- 113852-37-2
- Unique Ingredient Identifier
- 768M1V522C
- Background
Cidofovir is an injectable antiviral medication employed in the treatment of cytomegalovirus (CMV) retinitis in patients diagnosed with AIDS. It suppresses CMV replication through selective inhibition of viral DNA synthesis. It was manufactured by Gilead and initially approved by the FDA in 1996, but has since been discontinued.
- Indication
用于治疗免疫功能缺陷患者不能耐受更昔洛韦和膦甲酸钠治疗或治疗无效的巨细胞病毒感染。
- Associated Conditions
- Cytomegalovirus Retinitis, Herpes Simplex Virus, Monkeypox, Variola Major (Smallpox)
Clinical Trial for Evaluating the Efficacy and Safety of Electrocoagulation vs Topic Sinecatechins vs Topic Cidofovir Within the Treatment to High-grade Anal Intraepithelial Neoplasia in HIV Homosexual Males
- Conditions
- High-grade Anal Intraepithelial Neoplasia
- Interventions
- Procedure: electrocoagulation
- First Posted Date
- 2019-08-13
- Last Posted Date
- 2024-07-10
- Target Recruit Count
- 108
- Registration Number
- NCT04055142
- Locations
- 🇪🇸
Hospital U. Vall d'Hebrón, Barcelona, Catalunya, Spain
A Prolongation of a Clinical Study to Evaluate the Efficacy of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesions.
- Conditions
- High Grade Cervical Epithelial Neoplasia (CIN2+)
- Interventions
- First Posted Date
- 2016-11-30
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Brugmann University Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT02976987
- Locations
- 🇧🇪
CHU Brugmann Hospital, Brussels, Belgium
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir
- Conditions
- Cytomegalovirus (CMV)
- Interventions
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Shire
- Target Recruit Count
- 352
- Registration Number
- NCT02931539
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸Johns Hopkins Hospital, Baltimore, Maryland, United States
🇺🇸University of Southern California, Los Angeles, California, United States
Intralesional Cidofovir for the Treatment of Recalcitrant Warts in the Pediatric Immune-suppressed Population.
- First Posted Date
- 2015-10-02
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- University of Minnesota
- Registration Number
- NCT02567149
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
- Conditions
- Recurrent Respiratory Papillomatosis
- Interventions
- First Posted Date
- 2015-09-22
- Last Posted Date
- 2016-07-26
- Lead Sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
- Target Recruit Count
- 36
- Registration Number
- NCT02555800
- Locations
- 🇲🇽
Centro de Investigacion en Enfermedades Infecciosas, Mexico, Mexico
Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers
- Conditions
- Cervical Cancer
- Interventions
- First Posted Date
- 2015-08-05
- Last Posted Date
- 2016-06-09
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 15
- Registration Number
- NCT02515877
- Locations
- 🇫🇷
Gustave Roussy Cancer Campus Grand Paris, Villejuif, Val de Marne, France
A Prospective, With One Site, Open-label Not Controled Trial, for the Observation of Treatment With CIDOFOVIR 1%, 3 Nights Per Week, During 4 Weeks, of Anal Intraepithelial Neoplasia, High Level, in HIV+ Patients
- Conditions
- HIV
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Fundacion SEIMC-GESIDA
- Target Recruit Count
- 20
- Registration Number
- NCT01946009
- Locations
- 🇪🇸
Hospital Universitario La Paz, Madrid, Spain
Intravesical Cidofovir for Hemorrhagic Cystitis
- Conditions
- Blood And Marrow Transplantation
- Interventions
- First Posted Date
- 2013-03-22
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT01816646
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cidofovir Versus Best Supportive Care for Hemorrhagic Cystitis
- Conditions
- Transplantation Infection
- Interventions
- Other: No Cidofovir
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01295645
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions
- Conditions
- Uterine Cervical NeoplasmsCervix Intraepithelial Neoplasia
- Interventions
- First Posted Date
- 2009-10-05
- Last Posted Date
- 2010-10-21
- Lead Sponsor
- Mithra Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT00989443
- Locations
- 🇧🇪
Erasme Hospital, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.